A genomic region on distal mouse chromosome 1 and its syntenic human counterpart 1q23-42 show strong evidence of harboring lupus susceptibility genes. We found evidence of linkage at 1q32.2 in a targeted genome scan of 1q21-43 in 126 lupus multiplex families containing 151 affected sibpairs (nonparametric linkage score 2.52, P ‫؍‬ 0.006). A positional candidate gene at 1q32.2, complement receptor 2 (CR2), is also a candidate in the murine Sle1c lupus susceptibility locus. To explore its role in human disease, we analyzed 1,416 individuals from 258 Caucasian and 142 Chinese lupus simplex families and demonstrated that a common three-single-nucleotide polymorphism CR2 haplotype (rs3813946, rs1048971, rs17615) was associated with lupus susceptibility (P ‫؍‬ 0.00001) with a 1.54-fold increased risk for the development of disease. Single-nucleotide polymorphism 1 (rs3813946), located in the 5 untranslated region of the CR2 gene, altered transcriptional activity, suggesting a potential mechanism by which CR2 could contribute to the development of lupus. Our findings reveal that CR2 is a likely susceptibility gene for human lupus at 1q32.2, extending previous studies suggesting that CR2 participates in the pathogenesis of systemic lupus erythematosus.
S
ystemic lupus erythematosus [SLE (OMIM 152700)] is a chronic autoimmune disease characterized by circulating autoantibodies to nuclear antigens. Epidemiology, linkage, and association studies have provided compelling evidence for a genetic contribution to SLE susceptibility (reviewed in ref. 1) . Several loci linked to SLE reside on chromosome 1q, including 1q23 (2-4), 1q31 (2, 5) , and 1q41-43 (6) (7) (8) . Human chromosome 1q21-43 is syntenic to the distal end of mouse chromosome 1, where a recessive locus termed Sle1 has been strongly associated with lupus susceptibility (9) . Syntenic conservation in susceptibility intervals between mice and humans suggests the possibility that the same genes may confer risk for both murine and human lupus.
Sle1 corresponds to at least three loci (Sle1a, Sle1b, and Sle1c) (9) . The Sle1c interval contains the gene Cr2, which encodes complement receptors 1 and 2 (CR1 and CR2, CD35/CD21) by alternative splicing of a single mRNA transcript (10) . Cr2 is a major positional candidate gene of the murine Sle1c lupus susceptibility interval (11) . Its protein products are structurally and functionally altered because of a nonsynonymous amino acid change in the ligand-binding domain of CR2 that introduces a novel glycosylation site (11) .
In humans, several positional candidate genes on chromosome 1q have been associated with SLE (reviewed in ref. 12 ). However, there are no published reports of linkage or association at 1q32.2, where CR2 is mapped. The human CR2 gene (OMIM 120650) encodes a membrane glycoprotein, consisting of 15 repeating structures termed short consensus repeats (SCRs), that is expressed on mature B cells and follicular dendritic cells, as well as an alternatively spliced 16 SCR variant that is expressed primarily on follicular dendritic cells (13) . Its relative expression is primarily controlled at the level of transcription by the proximal promoter (14) (15) (16) (17) , and cell and lineage specificity of expression is regulated by an intronic silencer (18, 19) . CR2 binds C3 degradation products covalently bound to antigen in the process of complement activation, as well as EBV (20) , the immunomodulatory protein CD23 (21) , and IFN-␣ (22) . Cumulative studies suggest that CR2 plays a major role in immunity (reviewed in ref. 23 ). We report here linkage with lupus susceptibility in humans at 1q32.2 and provide compelling evidence that CR2 is an important gene in that region.
Results
Linkage to SLE at 1q32.2. A targeted genome scan of chromosome 1q21-43 for lupus susceptibility loci, which spanned the 108-cM interval at an average distance of 4 cM, showed evidence for linkage at 1q23 [peak at D1S2675, nonparametric linkage (NPL) ϭ 3.51, P ϭ 0.0002], 1q32.2 (peak at D1S205, NPL ϭ 2.52, P ϭ 0.006), and 1q41-42 (peak at D1S235, NPL ϭ 1.73, P ϭ 0.04) in 126 families containing 151 SLE-affected sibpairs (Fig. 1 ). This sample was extended from our previous cohort of multiethnic affected sibpair families (3, 4, 6) , in which we reported linkage to SLE at 1q23 and 1q41-42. In addition to providing support for the previously identified loci, this linkage analysis revealed a chromosomal region, 1q32.2, that may harbor SLE susceptibility genes.
Characterization of CR2.
To determine whether CR2 might contribute to the linkage at 1q32.2, we evaluated 10 CR2 singlenucleotide polymorphisms (SNPs) in a pilot study of 105 Caucasian SLE simplex families [including 38 SLE probands affected with lupus nephritis (LN) and 67 without LN] to characterize CR2 haplotype blocks. We selected 10 informative SNPs (minor allele frequency between 0.2 and 0.5) that included 5 potentially functional SNPs, e.g., 1 regulatory SNP [rs3813946 in the 5Ј untranslated region (UTR)] and 4 exonic SNPs (rs1048971 and rs17615 in exon 10, rs17616 in the alternatively spliced exon 10a, and rs6540433 in exon 17), and 5 haplotype-tagging intronic SNPs that tagged the two haplotype blocks (Fig. 2 A and B) . Only a single SNP (rs17615 G allele, G/A, S639N), located in the 19-kb block 1, showed evidence for association with SLE when the transmission-disequilibrium test (TDT) was used (transmission: nontransmission ϭ 44:26, P ϭ 0.03). SNP2 showed a trend of association (transmission:nontransmission ϭ 28:16, P ϭ 0.07) in the 67 non-LN families. Because none of block 2 SNPs (SNP 7-10) exhibited evidence for association, these data supported further analysis of haplotype block 1 SNPs for association with SLE.
Characterization of CR2 SNPs in Caucasian and Chinese Cohorts. We selected three SNPs in block 1 for further haplotype analyses in 258 Caucasian and 142 Chinese SLE simplex families. The SNP in exon 1 (rs3813946, SNP1; ϩ21 T/C) lies within the 5Ј UTR and could affect gene regulation, the synonymous SNP in exon 10 (rs1048971, SNP2; G/A, L592L) is a haplotype-tagging SNP in Caucasian and Chinese populations in the HapMap Phase I database (June 2005, www.hapmap.org), and the nonsynonymous SNP in exon 10 (rs17615, SNP3; G/A, S639N) was positively associated with SLE in our pilot study. The physical distance is 19 kb between SNP1 and SNP2 and 0.1 kb between SNP2 and SNP3 (Fig. 2 A) . The allele distribution of parental genotypes showed no deviation from Hardy-Weinberg equilibrium for each of these three SNPs. The minor allele frequency of each SNP in these families is shown in Table 1 . Parental allele frequencies were not different from those of the same ethnic group in the current HapMap Phase II database, but were significantly different between these two ethnic family collections (P ϭ 0.01, 0.001, and Ͻ0.0001 for SNP1, SNP2, and SNP3, respectively).
Association of CR2 SNPs and SNP Haplotypes with SLE Susceptibility.
Using the TDT family-based association method (24), we found that the major allele of each of the three CR2 SNPs was transmitted preferentially from heterozygous parents to their affected offspring in the Caucasian and Chinese families, and this overtransmission reached statistical significance in the combined sample (transmission:nontransmission ϭ 92:59, 159:122, 136:93, P ϭ 0.007, 0.03, and 0.005 for T at SNP1, G at SNP2, and G at SNP3, respectively, Table 1 ). Consistent with these results, the major alleles were not preferentially transmitted to unaffected offspring in these families (data not shown).
The two-locus CR2 SNP haplotypes span 18.6 kb (SNP1 and SNP2), 0.14 kb (SNP2 and SNP3), and 18.7 kb (SNP1 and SNP3). Pairwise linkage disequilibrium (LD) in both Caucasian (DЈ ϭ 0.80-0.84, r 2 ϭ 0.28-0.52) and Chinese (DЈ ϭ 0.79-0.87, r 2 ϭ 0.27-0.62) cohorts (Fig. 2C) showed that, in both populations, these three SNPs were independently informative and were contained within a single haplotype block, which was similar to the block structure in the current HapMap Phase II database (January 2006) and consistent with our pilot study. Table 2 gives the frequencies of major allele SNP haplotypes in both Caucasian and Chinese parents. Although parental haplotype distributions of these two cohorts were significantly different (P from Ͻ0.0001 to 0.0007 for two-or three-locus haplotypes), SNP haplotypes formed by the major allele of these three SNPs were preferentially transmitted to affected offspring in both cohorts, as well as in the combined 400 families (haplotype P ϭ 0.00001-0.0008, global P ϭ 0.0001-0.002, Table 2 ). As with the individual SNPs, the major allele SNP3 haplotype was not preferentially transferred to unaffected siblings in these families (data not shown). These data provided evidence that CR2 is a good candidate gene for SLE risk in 1q32.2.
Differences in CR2 SNP Allele Frequencies in Family-Based Cases and
Controls. The affected family-based controls approach (25) can create controls by subtracting alleles in affected SLE children from parental alleles in complete trios. The case versus control allele frequencies are estimated from the parental transmitted versus nontransmitted alleles to the affected children. As expected from the TDT results, the major allele frequencies of the CR2 SNPs were significantly higher in SLE offspring (88%, 74%, and 82% for SNP1, SNP2, and SNP3, respectively) when compared with the controls (82%, 69%, and 75%) in the total cohort {odds ratio ϭ 1.53 [95% confidence interval (C.I.) ϭ 1.11-2.10], 1.32 [95% C.I. ϭ 1.04-1.68], and 1.47 [95% C.I. ϭ 1.13-1.92]}. Although no direct estimate of the frequency of the major allele CR2 haplotype can be made from the trio data, the frequency was estimated by using the expectation-maximization algorithm in the affected offspring, and the parental frequencies were inferred by subtraction. When this approach was used, the major allele CR2 haplotype frequency was higher in SLE offspring compared with controls (71% vs. 62%). Treating these inferred haplotypes as determined, their frequencies are significantly different [P ϭ 0.0007, odds ratio ϭ 1.54 (95% C.I. ϭ 1.21-1.96)]. These results supported our hypothesis that the major alleles for the CR2 SNPs in haplotype block 1 conferred risk for the development of SLE. 
Preferential Transmission of the Major CR2 SNP Alleles to SLE Patients
Without Renal Involvement. Involvement of the kidneys in SLE is one of the most serious complications of this disease. To assess whether the major allele CR2 SNP haplotype was associated with the development of LN, we stratified the SLE families by the presence or absence of LN (26) in the SLE proband within each family. Overtransmission of the haplotype formed by the major alleles of CR2 SNPs was observed mainly in SLE patients without renal involvement (haplotype P ϭ 0.0001-0.002, global P ϭ 0.002-0.02) ( Table 3) . Although various other clinical features of SLE might not be independently manifested, stratification on each SLE subphenotype revealed a strong positive association of the identified CR2 haplotype with malar rash, photosensitivity, oral ulcers, serositis, anti-cardiolipin antibodies, anti-Sjögren's Syndrome A antibodies, and anti-dsDNA antibodies (data not shown).
SNP1 Regulates CR2 Transcription. Several motifs in the human CR2 proximal promoter are involved in controlling promoter activity (Fig. 3A) . These motifs include cell type-specific elements (16), as well as activator and repressor motifs that function in all tested cell lines (17) . Although the Ϫ315/ϩ75 region of the CR2 promoter is known to contain all of the factors necessary for basal transcription (17) , sequences in the 5Ј UTR of the gene have never been examined for functional relevance. To evaluate the effect of SNP1 on basal CR2 transcription, luciferase (Luc) constructs containing the CR2 promoter region spanning Ϫ315/ ϩ75 and expressing either the major T allele or the minor C allele at position ϩ21 were generated and transiently transfected into the CR2-expressing Raji B lymphoblastoid cell line. Expression of the major ϩ21 T (Fig. 3B, CR2 ϩ21T /Luc, n ϭ 6) allele resulted in a 2-fold increase in transcriptional activity compared with expression of the minor C allele (Fig. 3B , CR2 ϩ21C /Luc, n ϭ 10; P ϭ 0.0089). In addition, although mean CR2 mRNA expression in peripheral blood mononuclear cells from healthy controls homozygous for the major T allele was not significantly higher than that of the other two groups ( Fig. 3C ; P ϭ 0.59 for TT vs. CT ϩ CC), all of the individuals expressing the highest levels of CR2 mRNA were homozygous for this allele. These data suggest that sequences within the CR2 5Ј UTR, and specifically those surrounding SNP1 at position ϩ21, regulate CR2 promoter activity, and this regulation may have implications in lupus pathogenesis.
Discussion
We describe here evidence of linkage for human lupus susceptibility at chromosome 1q32.2, where CR2 is mapped, and the positive association between CR2 SNPs and a CR2 SNP haplotype with lupus susceptibility in two distinct ethnic groups. Furthermore, SNP1 in the associated haplotype, which is located in the 5Ј UTR of the CR2 promoter, may be functionally relevant and could affect susceptibility to SLE. Together with previous data suggesting that Cr2 is a strong candidate gene for lupus susceptibility in a syntenic region of the mouse genome, and multiple lines of evidence suggesting that CR2 plays an important role in immunity and autoimmunity, our findings strongly support the hypothesis that CR2 variants predispose their carriers to SLE.
Family-based TDT analysis showed significant association of the major allele CR2 haplotype with SLE susceptibility [haplotype P ϭ 0.00001, permuted P ϭ 0.0047 (from 1,000,000 random iterations of the haplotype data by Haploview software)]. We estimated that the risk of developing SLE is 1.54-fold higher for individuals who carry the major allele CR2 haplotype. Although these studies also supported an association of the major allele CR2 haplotype with non-LN SLE, they lacked the statistical power to rule out an association of this haplotype with LN. Our initial analysis of the functional effects of SNPs in this haplotype revealed that the major T allele for SNP1 results in a 2-fold increase in promoter activity. This allele is also associated with increased transcription factor binding at the DNA, but not the RNA level (D.U., unpublished data). Individuals expressing the highest levels of CR2 were all homozygous for this allele, suggesting that this SNP alters transcriptional activity of the promoter in vivo.
Increased expression of CR2 regulated by SNP1 could promote the development of autoimmunity by several mechanisms. CR2 lowers the threshold for B cell activation, and autoreactive B cells in individuals genetically predisposed to express more CR2 may be easily activated when they encounter complementcoated immune complexes containing self-antigen. Furthermore, increased CR2 expression may alter B cell responses to IFN-␣ and EBV, two alternative ligands for human CR2 that have been implicated to play a role in SLE. Finally, alterations in CR2 expression have a variety of different effects on manifestations of disease in animal models of autoimmunity (27) (28) (29) (30) , suggesting that tight regulation of this receptor is critical in the induction and maintenance of tolerance. The specific effects of dysregulated expression likely depend on the cell type affected and the time in ontogeny when expression is altered. Although CR2 levels are decreased by Ϸ50% on B cells of patients with SLE (31, 32) , this decrease may be the result of multiple factors, including alterations in B cell homeostasis, immune complex formation and deposition, and alterations in the cytokine milieu associated with active disease. The presence of low CR2 levels in individuals with established disease does not exclude the possibility that levels were increased before disease onset.
Other SNPs in the identified risk CR2 haplotype may also have functional effects that could predispose to SLE. For example, SNP3, which is located in exon 10 of the CR2 gene, was the only SNP that was independently associated with SLE in our pilot study. Exon 10 is positioned directly 5Ј of the alternatively spliced exon 10a, which is found in a long CR2 isoform almost exclusively expressed on follicular dendritic cells (13) . SNPs in coding domains can alter pre-mRNA splicing and message stability (33) , and an SNP3 allelic variant may regulate the relative level of the long and short isoform of CR2. Furthermore, the major allele for SNP3 substitutes an asparagine for a serine, which is conserved in mice, rats, and sheep, suggesting that it may be important in receptor function.
These data provide initial evidence for a role for CR2 in human lupus susceptibility. We have identified a risk CR2 haplotype containing a major allele for a regulatory SNP that may influence disease development as a result of increased receptor expression, as well as two other major allele SNPs that may also be functional. Nevertheless, we cannot rule out the possibility that these SNPs are in LD with SNPs in this or other CR2 haplotype blocks, or in other genes surrounding CR2 at chromosome 1q32.2, including the 94-kb upstream decay accelerating factor (DAF) CD55 and the 6-kb downstream CR1 (Fig.  2D Upper) . Data from the HapMap project (Phase II, July 2006; Fig. 2D Lower) show no/low LD of SNP1-3 with 39 variants of DAF (pairwise DЈ ϭ 0.07-1, r 2 ϭ 0-0.1 for Caucasian; DЈ ϭ 0.6-1, r 2 ϭ 0.001-0.2 for Chinese), strong LD with SNPs located within the Ϸ50-kb intergenic upstream region, a break in LD with SNPs located within the 3Ј region of CR2, and some LD with 5Ј CR1 SNPs in Caucasians and Chinese and 3Ј CR1 SNPs in Caucasians only (r 2 Ն 0.3, DЈ Ͼ 0.5). Therefore, although these data most strongly implicate the haplotype block containing SNP1-3 in the association with SLE that we demonstrate here, it is possible that CR1 SNPs or CR2 SNPs in other haplotype blocks are involved in this association. Only after a thorough and careful analysis of the haplotype block structure of CR2 and CR1, in combination with functional assessments of any associated SNPs, will we be able to assign causality to a specific CR2 SNP. Microsatellite Marker Genotyping. Genomic DNA was isolated from peripheral blood mononuclear cells by using a standard protocol. A total of 25 microsatellite markers (D1S305, D1S2635, D1S2771, D1S2675, D1S1677, D1S2628, D1S431, D1S2851, D1S2790, D1S1589, D1S518, D1S1660, D1S2872, D1S2685, D1S2891, D1S491, D1S205, D1S2810, D1S2703, D1S2629, D1S2827, D1S229, D1S2871, D1S235, and D1S547) spanning 108 cM on 1q21-43 were genotyped by using fluorescent-based PCR. The marker information and sequences of PCR primers for each marker are as shown on the public website (http://www.ncbi.nlm.nih.gov/genome/unists). Microsatellite PCR and genotyping analysis were conducted as described in ref. 3 . CR2 SNP Genotyping. CR2 SNPs were genotyped by pyrosequencing (34) . PCR primers were designed by using Primer3 software (http://frodo.wi.mit.edu/cgi-bin/primer3/primer3www.cgi) to generate amplicons of Ͻ 200 base pairs. Sequencing primers were designed by using SNP Primer Design Software Version 1.01 (http://primerdesign.pyrosequencing.com/jsp/TemplateInput.jsp). PCR and pyrosequencing of each SNP were performed as described in ref. 35 . Forward primer 5Ј-CGTGTGCCGGACAC-TATTTA-3Ј, reverse primer 5Ј-CGACGAGAGCCAAGAAA-ACC-3Ј, and sequencing primer 5Ј-GCAGCTCTGGGAGG-3Ј were used for SNP1; forward primer 5Ј-GAGAGAGCACCATC-CGTTGT-3Ј, reverse primer 5Ј-GCAAGGAGGGAAAGTT-3Ј, and sequencing primer 5Ј-GCAGCTCTGGGAGG-3Ј were used for SNP2; and forward primer 5Ј-TTGCTGTCCAGTGCTCA-CAT-3Ј, reverse primer 5Ј-TGGTATTTCAGGATCCCAGGT-3Ј, and sequencing primer 5Ј-TTTACTTTGAAGGGCA-3Ј were used for SNP3. Seven non-Mendelian Interitance were detected in the Caucasian and Chinese cohorts, and those samples for that marker were excluded from further analysis.
Methods
Creation of CR2 Promoter/Luciferase Fusion Constructs. An NheI/ XhoI fragment of the CR2 promoter containing nucleotides Ϫ315/ϩ75 with the major T allele at position ϩ21 was previously cloned into the luciferase reporter pGL3-basic vector (Clontech, Mountain View, CA) (16) . Site-directed mutagenesis was performed by using the QuikChange mutagenesis kit (Stratagene,
